- Home
- ZEPP vs IMMX Comparison
ZEPP vs IMMX Comparison
Compare ZEPP & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEPP
- IMMX
- Stock Information
- Founded
- ZEPP 2013
- IMMX 2014
- Country
- ZEPP China
- IMMX United States
- Employees
- ZEPP N/A
- IMMX N/A
- Industry
- ZEPP Computer Manufacturing
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- ZEPP Technology
- IMMX Health Care
- Exchange
- ZEPP Nasdaq
- IMMX Nasdaq
- Market Cap
- ZEPP 57.5M
- IMMX 51.1M
- IPO Year
- ZEPP N/A
- IMMX 2021
- Fundamental
- Price
- ZEPP $3.43
- IMMX $1.38
- Analyst Decision
- ZEPP
- IMMX Strong Buy
- Analyst Count
- ZEPP 0
- IMMX 1
- Target Price
- ZEPP N/A
- IMMX $7.00
- AVG Volume (30 Days)
- ZEPP 34.4K
- IMMX 148.3K
- Earning Date
- ZEPP 11-18-2024
- IMMX 11-11-2024
- Dividend Yield
- ZEPP N/A
- IMMX N/A
- EPS Growth
- ZEPP N/A
- IMMX N/A
- EPS
- ZEPP N/A
- IMMX N/A
- Revenue
- ZEPP $237,238,260.00
- IMMX N/A
- Revenue This Year
- ZEPP N/A
- IMMX N/A
- Revenue Next Year
- ZEPP $18.83
- IMMX $200.00
- P/E Ratio
- ZEPP N/A
- IMMX N/A
- Revenue Growth
- ZEPP N/A
- IMMX N/A
- 52 Week Low
- ZEPP $2.06
- IMMX $1.26
- 52 Week High
- ZEPP $8.40
- IMMX $7.75
- Technical
- Relative Strength Index (RSI)
- ZEPP 49.37
- IMMX 37.03
- Support Level
- ZEPP $3.10
- IMMX $1.26
- Resistance Level
- ZEPP $3.60
- IMMX $1.51
- Average True Range (ATR)
- ZEPP 0.27
- IMMX 0.16
- MACD
- ZEPP -0.07
- IMMX -0.00
- Stochastic Oscillator
- ZEPP 25.78
- IMMX 20.37
About ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in two segments: Xiaomi Wearable Products and Self-branded products & others. The product portfolio includes smartwatches and fitness bands. The majority is from Self-branded products & other segments. It generates majority of the revenue from Xiaomi Wearable Products segment.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.